Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RNA sequencing Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

NCT00500812
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Cethrin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
16 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 17, 2026, 8:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Capturing Autobiographical Memory Formation in Real World Spaces Using Multimodal Recordings

NCT06883981
View directory record Official record
Conditions
Epilepsy, Autobiographical Memory
Interventions
Free and Cued Recall Memory. Temporal Sequence and Spatial Memory
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness-Based Art Therapy and Generation Z

NCT04834765
View directory record Official record
Conditions
Anxiety Depression
Interventions
Mindfulness-based art therapy, Art-only, Mindfulness-only
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 25 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

NCT02334501
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy

NCT03262181
View directory record Official record
Conditions
Tendinopathy
Interventions
Isometric Exercise, Sham Transcutaneous Electrical Nerve Stimulation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 28 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

NCT01846481
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
Interventions
RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

NCT01069822
View directory record Official record
Conditions
Healthy
Interventions
AZD6765, midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 17, 2026, 8:53 AM EDT
Withdrawn No phase listed Observational

Personalizing Immune Checkpoint Inhibitor Therapy

NCT03409341
View directory record Official record
Conditions
Lung Cancer Stage IV
Interventions
Blood and tumor tissue analysis, Clinical response.
Other
Lead sponsor
Holy Cross Hospital, Maryland
Other
Eligibility
18 Years to 70 Years
Timeline
2019 – 2020
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

NCT03647202
View directory record Official record
Conditions
Food Effects on Pharmacokinetics
Interventions
Milademetan Treatment A, Milademetan Treatment B, Milademetan Treatment C
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 8:53 AM EDT
Active, not recruiting No phase listed Observational

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03281902
View directory record Official record
Conditions
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Interaction Study With Ranitidine

NCT01908257
View directory record Official record
Conditions
Healthy
Interventions
lesinurad 400 mg, ranitidine 150 mg, lesinurad 400 mg + ranitidine 150 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops

NCT05814367
View directory record Official record
Conditions
Visual Acuity
Interventions
Blink® Tears eye drops in a multidose bottle, Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Drug
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Jacksonville, Florida • Maitland, Florida • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Home Exercise Program for Women With Infants & Young Children

NCT01738984
View directory record Official record
Conditions
MomZing Exercise Videos Online, Standard Exercise DVD
Interventions
MomZing Web Program, Standard Exercise DVD
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 8:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Brain Stimulation on Learning and Reasoning

NCT00001776
View directory record Official record
Conditions
Cerebellar Disease, Dementia, Healthy, Parkinson's Disease
Interventions
Cadwell Rapid Rate Magnetic Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

NCT01844674
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Tizanidine, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Pleasant Hill, California • Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 17, 2026, 8:53 AM EDT
Recruiting Phase 4 Interventional

Allograft Dysfunction in Heart Transplant

NCT03102125
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
Regadenoson
Drug
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 8:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 17, 2026, 8:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism

NCT02624791
View directory record Official record
Conditions
Astigmatism
Interventions
1-DAY ACUVUE® MOIST contact lenses, 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses, No contact lenses
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 39 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 17, 2026, 8:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Identify the Genetic Variations Associated With Phantom Limb Pain

NCT01462448
View directory record Official record
Conditions
Phantom Limb
Interventions
Blood Draw
Procedure
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 17, 2026, 8:53 AM EDT